Please login to the form below

Not currently logged in
Email:
Password:

GSK announces combination approval for Avodart

GlaxoSmithKline has announced that the US Food and Drug Administration has approved Avodart in combination with tamsulosin (Flomax) for the treatment of symptomatic enlarged prostate
GlaxoSmithKline (GSK) has announced that the US Food and Drug Administration (FDA) has approved Avodart in combination with tamsulosin (Flomax) for the treatment of symptomatic enlarged prostate.

Half of all men over 50 years old are affected by enlarged prostate. The two-year study into the use of Avodart combined with tamsulosin showed that in combination the medicines were more effective than single drug therapies at treating common symptoms such as nocturia.

Both drugs already have FDA approval for use singularly in the treatment of enlarged prostate. "The combination of Avodart and tamsulosin at diagnosis allows doctors to simultaneously treat the patient's prostate on two fronts by reducing prostate size and rapidly improving symptoms," said Dr Steven A Kaplan, from Weill Cornell Medical College of Cornell University in New York City.

The randomised, double-blind study of the combination of Avodart and tamsulosin is one of the largest clinical trials to date involving men with enlarged prostate. It was the first long term assessment of the combination of Avodart, which works by suppressing the male hormone responsible for the enlargement of the prostate, and an alpha-blocker.

23rd June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics